You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,662,322


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,662,322
Title:Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
Abstract: This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.
Inventor(s): Knappertz; Volker (Potomac, MD)
Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva, IL)
Application Number:14/946,586
Patent Claims:1. A method of reducing deterioration of ambulation of a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and to have a baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS) of greater than 3, comprising periodically administering to only the patient diagnosed with RRMS and having a baseline EDSS score of greater than 3 an amount of laquinimod effective to reduce deterioration of the patient's ambulation.

2. The method of claim 1, wherein the amount of laquinimod is effective to reduce the patient's relapse rate.

3. The method of claim 1, wherein the amount of laquinimod is effective to reduce the patient's accumulation of physical disability.

4. The method of claim 1, wherein ambulation is assessed by the patient's Timed-25 foot walk test score.

5. The method of claim 1, wherein laquinimod is administered orally and/or daily.

6. The method of claim 1, wherein laquinimod is administered at a daily dose of 0.3 mg laquinimod.

7. The method of claim 1, wherein laquinimod is administered at a daily dose of 0.6 mg laquinimod.

8. The method of claim 1, wherein laquinimod is administered as adjunct therapy with another RRMS treatment.

9. The method of claim 8, wherein the other RRMS treatment is administration of interferon beta 1-a, interferon beta 1-b, glatiramer acetate, mitoxantrone or natalizumab.

10. A method of reducing deterioration of ambulation of a human patient diagnosed to be afflicted with RRMS, worsening MS and to have a baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS) of greater than 3.0, comprising periodically administering to only the patient diagnosed with RRMS, worsening MS and having an EDSS score of greater than 3.0 an amount of laquinimod effective to reduce deterioration of the patient's ambulation.

11. The method of claim 10, wherein laquinimod is administered orally and/or daily.

12. The method of claim 10, wherein laquinimod is administered at a daily dose of 0.3 mg laquinimod.

13. The method of claim 10, wherein laquinimod is administered at a daily dose of 0.6 mg laquinimod.

14. The method of claim 10, wherein laquinimod is administered as adjunct therapy with another RRMS treatment.

15. The method of claim 14, wherein the other RRMS treatment is administration of interferon beta 1-a, interferon beta 1-b, glatiramer acetate, mitoxantrone or natalizumab.

16. The method of claim 1, wherein the patient has mobility impairment.

17. The method of claim 1, wherein the patient has a baseline EDSS score of 3.5-5.5.

18. The method of claim 1, wherein the laquinimod is laquinimod sodium.

19. The method of claim 16, wherein the mobility impairment is an ambulatory impairment.

20. The method of claim 19, wherein the patient is not ambulatory.

21. The method of claim 10, wherein the amount of laquinimod is effective to reduce the patient's relapse rate.

22. The method of claim 10, wherein the amount of laquinimod is effective to reduce the patient's accumulation of physical disability.

23. The method of claim 10, wherein ambulation is assessed by the patient's Timed-25 foot walk test score.

24. The method of claim 10, wherein the patient has a baseline EDSS score of 3.5-5.5.

25. The method of claim 10, wherein the laquinimod is laquinimod sodium.

26. The method of claim 10, wherein the patient has mobility impairment.

27. The method of claim 26, wherein the mobility impairment is an ambulatory impairment.

28. The method of claim 27, wherein the patient is not ambulatory.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.